On July 9, 2009, Rigel Pharmaceuticals, Inc. issued a press release announcing results of its TASKi2 Phase 2b clinical trial of R788 (fostamatinib disodium). The press release, dated July 9, 2009, entitled "Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial" is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

(d) Exhibits.

Exhibit No.                                 Description

99.1           Press Release, dated July 9, 2009, entitled "Rigel's R788
               Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical
               Trial".